immune effector cell-associated toxicity syndrome (LICATS)
Jump to navigation
Jump to search
Etiology
- chimeric antigen receptor (CAR) T-cell therapy
- treatment with CD19-targeting CAR T cells
Epidemiology
- 3/4 of patients undegoing CAR T-cell therapy
Clinical manifestations
- most cases mild in intensity
- most frequently affected organs were the skin (35%) & kidneys (22%)
- resolves within a couple weeks without further incident
- probably reflects beneficial effects of treatment*
* most likely "cleansing of immune cells from the affected organs"
* self-limited, organ-specific, & generally mild
More general terms
References
- ↑ Hagen M, Muller F, Wirsching A et al Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 2025 Apr 30:S2665-9913(25)00091-8. PMID: https://pubmed.ncbi.nlm.nih.gov/40318690 Free article. https://www.sciencedirect.com/science/article/pii/S2665991325000918